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Conclusions. Patients with atherosclerotic RAS fulfilling strict Background. Prior studies of percutaneous transluminal recriteria of severity may have significant improvements in BP nal artery angioplasty and stenting (PTRAS) for atherosclerotic one year after PTRAS but only modest in GFR. The initial renal artery stenosis (RAS) have shown that renal function is GFR may anticipate whether the benefits in the outcome will improved in about 25%, stabilizes in about 40%, but worsens be in renal function enhancement (those with an initially dein about 25% of patients. The factors predicting benefit remain pressed GFR) or in hypertension control (those with an initially controversial. We tested the hypothesis that the baseline glonormal or mildly impaired GFR). merular filtration rate (GFR) predicts the changes in GFR and blood pressure (BP) after PTRAS.
Methods. Treated hypertensive patients with positive renal color-coded duplex Doppler velocimetry and clinical criteria
Renal artery stenosis (RAS) causing renovascular diswere screened by arteriography. Patients (N ϭ 105) were included ease was considered a rare cause of secondary hypertenif they had an RAS Ն70%, a transluminal pressure gradient sion. However, with improvements in techniques for Ն30 mm Hg and, they had more than 100 days of follow-up. GFR was calculated from the serum creatinine concentration screening and with the widespread use of vascular im-(S Cr ). Patients were divided by baseline GFR into subgroups aging, it is now recognized that 40 to 50% of patients with normal to mildly impaired (N ϭ 52) or moderately to with occlusive disease of the lower limb [1] and 15 to 30% severely impaired (N ϭ 53) initial GFR, according to a GFR of patients with coronary artery disease have identifiable Ն50 or Ͻ50 mL · min Ϫ1 respectively. All received PTRAS.
RAS [2] . Reports of patients with established, or newly meta-analyses of the seven trials reporting surgical intervention and of four reporting intervention with PTRAS  2003 by the International Society of Nephrology indicates that 25 to 30% had an improvement in GFR, tion recommendations [10] . Reported values for each subject are the average of three separate readings. 45 to 50% had a stable GFR, whereas 20 to 25% had a decline in GFR at follow-up [7, 8] . The failure to show Renal function was assessed from measurements of serum creatinine concentration (S Cr ) and application of statistically significant effects of intervention on GFR in individual studies was due to a similar number of those the Cockroft and Gault formula [11] to estimate the glomerular filtration rate (GFR; mL · min
Ϫ1
) according who improved or who deteriorated [7] . Therefore, it becomes critical to define subgroups of patients with to the S Cr (mg · dL Ϫ1 ), weight (kg), age (years) and gender RAS who may have an improvement in BP or GFR after of the patient: intervention.
GFR (males) ϭ [(140 -age) ϫ body weight]/(S Cr ϫ 72) We tested the hypothesis that, in selected patients with quite severe RAS, the preexisting level of renal function GFR (females) ϭ Value for males ϫ 0.85 might predict a group of patients who will experience a Renal arteriography was performed through a femoral favorable GFR and/or BP response to intervention with artery access with a guided 8-French catheter placed in PTRAS.
the aorta to study selectively all renal arteries. Thereafter, if a renal artery stenosis Ն70% was detected, further METHODS views were undertaken (in the anteroposterior and coronal planes) to confirm the degree of luminal stenosis The Ethical Review Board of the Favaloro Foundation from the arteriographic photographs. The catheter was in Buenos Aires, Argentina where all of these studies advanced across the stenosis and the pressure gradient were conducted, authorized the study. Informed consent established, and in those cases with critical RAS the was required in all participants. Patients selected were thinnest available catheter was employed. Whenever a those at risk for RAS according to clinical criteria (JNC stenosis was considered hemodynamically significant VI stages II-III or resistant hypertension, or associated (Ͼ30 mm Hg pressure gradient), PTRA was performed renal failure or atherosclerotic vascular disease) and a with a Tittan balloon where the width and length were positive screening test utilizing renal ultrasound with selected according to the anatomy of the stenosis. Therecolor-coded duplex Doppler velocimetry of the renal after, a Palmaz Schatz stent was implanted over a Cordis arteries (HP SONOS 2500, with 2.5 and 3.5 MHz probes).
balloon, which was inflated to 10 to 12 atmospheres or Single operator echographic sensitivity and specificity as necessary to produce a good anatomical result [12] . for repeated measurements for stenosis over 60% were
Complications observed after the procedure were two both 97% (analysis of 343 arteries). There was a significases of bleeding and large inguinal hematoma with an cant correlation between the quantitative estimations of hematocrit drop of more than 5%, and one case of right the degree of RAS by the duplex Doppler velocimetry perirenal hematoma during a bilateral stenting procemethod with the values obtained subsequently by arteridure managed conservatively without afterward clinical ography (r ϭ 0.79, P Ͻ 0.001). From an initial sample consequences. of 149 patients, a study group of 105 was obtained with
The following definitions were applied: significant atherosclerotic renovascular stenosis (detailed later in this article), and a follow-up evaluation after at least 100 days. A number of 44 patients were excluded Hypertension: systolic blood pressure (SBP) Ն140 mm Hg and/or diastolic blood pressure (DBP) Ն90 because they (a) had a RAS Ͻ70% in arteriography and did not undergo PTRAS (N ϭ 27); (b) received angiomm Hg, calculated as the average of three separate blood pressure recordings, or the need for current plasty without stenting (N ϭ 2); (c) were submitted to surgery (N ϭ 2); (d) had a primary stent failure (N ϭ 1) ; antihypertensive therapy. Significant renal artery stenosis: Ն70% luminal reducand (e) were lost to follow-up (N ϭ 12). The follow-up after PTRAS averaged 371 days (median 376, range 100 tion of a renal artery and a pressure gradient of Ն30 mm Hg across the lesion. to 700). Only patients with primary technical success following PTRAS were included [9] . Inclusion in the study Bilateral renal artery stenosis: Ն50% bilateral luminal reductions. At variance with the former definition, required at least two clinic visits following the intervention. Routine laboratory tests and a second renal ultraa lower limit was used only in order to characterize a subgroup of patients with higher extension of athsound study were undertaken in all study patients at the last of these visits. Blood pressure data were the average erosclerotic renal artery disease suggesting a higher risk of disease progression, but stenting were limited values obtained before the intervention and at the last of the follow-up evaluations, both under prescribed antionly to those defined as significant RAS. Cure of hypertension: SBP Ͻ140 mm Hg and DBP Ͻ90 hypertensive treatments. A trained operator measured BP with a mercury sphygmomanometer after two minmm Hg in the absence of antihypertensive therapy. Renal function according to GFR: normal to mildly utes of sitting, according to the American Heart Associa- , moderate to severely tensive and receiving drug treatment, but only 26 (25%) were controlled. Renal artery stenosis was found bilatimpaired Ͻ50 mL · min Ϫ1 .
eral in 45 (43%) patients. Of these, 18 (40%) underwent Primary technical success after PTRAS: residual stebilateral PTRAS. A total number of 123 stents were nosis Ͻ50% and a pressure gradient Ͻ5 mm Hg withapplied and 33% of patients presented with ostial renal out major complications (surgery required or death).
artery stenosis.
Statistical analysis
The BP and renal function at baseline before PTRAS and at follow-up is detailed in Table 2 . For the group as Data are expressed as mean values Ϯ standard deviaa whole, there was a highly significant reduction in BP, tion. To assess within-patient changes, a paired t test was a modest, but significant, reduction in S Cr , and a conseapplied, or Wilcoxon signed-rank test for paired nonquent increase in the calculated GFR. normal distributed variables (serum creatinine). The popAs shown in Figure 1 , it is apparent from the subulation sample was analyzed as a whole and by subgroups group's analysis that the outcome of PTRAS diverged selected according to renal function as defined above.
upon the initial level of GFR. Thus, a significant improveDifferences between subgroups were analyzed by unpaired ment in BP control occurred only in the subgroup with t test. Univariate and multivariate regression analysis initially higher renal function. Conversely, a reduction and 2 tests were applied when appropriate (GB-STAT in the S Cr and an improvement in the calculated GFR version 7.0; Dynamic Microsystems, Inc., Silver Spring, occurred only in the subgroup with initially more impaired MD, USA). A further analysis of the variation observed renal function. After application of the correction for reat follow-up in the calculated GFR was undertaken after gression toward the mean, the improvement in renal funccorrection in baseline GFR for the expected regression tion in the subgroup of patients with initially impaired toward the mean (RTM). This analysis was required renal function remained highly significant ( Table 2) . because of the selection process of subgroups according After PTRAS there was a considerable improvement to baseline renal function [13] . For this purpose, the in hypertension control. Overall, the fraction of patients Shepard and Finison formula was applied [14] [15] [16] . A rewith normotension increased from 25% at baseline to peatability correlation index for GFR of 0.7 was applied.
65% after PTRAS, including 19 patients who were cured Differences were considered significant at P Ͻ 0.05. of hypertension. A reduction in the number or doses of antihypertensive drugs prescribed was observed in 67% RESULTS of the patients who still required treatment. The clinical characteristics of the study population at Univariate regression analysis demonstrated a signifibaseline are summarized in Table 1 . No differences in cant negative correlation between the baseline GFR and the analyzed variables were found between subgroups, the follow-up values for SBP (r ϭ Ϫ0.29, P ϭ 0.0026) with the exception of the number of prescribed antihyand DBP (r ϭ Ϫ0.33, P ϭ 0.0006). After a multivariate pertensive drugs, which were higher in the group with stepwise regression analysis including age, baseline systolic (SBP) and diastolic (DBP) blood pressure, and more impaired renal function. All patients were hyper- GFR at follow-up as covariates, the relationship between Those with an initially elevated S Cr had a significant improvement in their calculated GFR, despite no apparent SBP and DBP at follow-up as dependent variables with benefit in their BP (BP decreased, though non-signifibaseline GFR remained significant. This indicates that cantly). In contrast, those with an initially normal S Cr had a a low GFR value at baseline emerged as a negative significant improvement in their BP despite no apparent predictor of PTRAS to reduce the systolic and diastolic changes in their calculated GFR. As anticipated, the reblood pressure at follow-up. stenosis rate was higher in patients with ostial stenosis, A post-hoc subgroup analysis showed that bilateral but remained low (14%) after one year of follow-up. renal artery stenosis, which was detected in 45 patients,
The subgroups did not differ in their demographics, apparently did not influence the changes in blood presthe levels of systolic and diastolic BP, the presence of sure or GFR after intervention, although this conclusion comorbid conditions, risk factors, bilateral RAS, the rate is based on a limited number of patients. In 93% of of bilateral stenting or the fraction with ostial lesions. patients, renal artery patency after stenting was evaluBy design, they had significant differences at baseline in ated at follow-up using color duplex Doppler velocimetheir levels of renal function. We evaluated whether try. A re-stenosis was detected in 14 patients (14%). This these results could be ascribed to the phenomenon of was more likely in those with ostial lesions (27 vs. 8%; regression toward the mean (RTM), since bias will occur P Ͻ 0.02 by Yates-corrected 2 ) .
when a population is divided into groups according to one variable, and measurements are made sequentially DISCUSSION with that variable as the outcome measure. In this cirThis study was conducted in 105 patients, who all undercumstance, even in the absence of a real change, the went a PTRAS after applying quite strict criteria for RAS data for the two groups will converge [13] [14] [15] [16] . Thus, requiring intervention. They were screened by clinical subsequent trends in the data for each group could be criteria and by positive renal artery color-coded duplex the effects of selection. The degree of RTM depends on Doppler velocimetry test. Entry required arteriographic the spontaneous variability of the parameter over time findings of anatomical RAS Ն70% and hemodynamic and on the differences between the individual mean valsignificance as evidenced by a gradient in arterial presues of the subgroups from the whole population [13, 16] . sure across the stenosis Ն30 mm Hg. Blood pressure and A statistical correction was made in the baseline calcu-S Cr were evaluated before and at an average of one year lated GFR to compensate for the effects of RTM. Using after the intervention. The group as a whole had a sigthis correction, the modest increase in the S Cr and denificant improvement in their BP and calculated GFR, crease in the calculated GFR after intervention in the without important clinical complications or individuals subgroup of patients with initially normal renal function with renal function deterioration. However, the main was judged not statistically significant, while the more robust improvements in these variables in the subgroup new findings were disclosed in the subgroup analysis.
16% of patients with RAS who received only medical therapy progressed to complete occlusion of the affected renal artery over one year [5] . Therefore, the overall gain in the calculated GFR over one year can reasonably be ascribed to the intervention, rather than to a spontaneous improvement. Last, the study conclusions are valid only for the one-year period during which this group of patients was observed, and according to a non-standardized antihypertensive treatment. Long-term morbidity and mortality are important objectives that were not addressed in this study.
An apparent recent increase in the prevalence of RAS [7, [20] [21] [22] [23] has coincided with a more widespread availability of PTRA(S). Even the casual finding of RAS at the time of coronary or ilio-femoral arteriography can prompt a PTRA(S) in the hope of preserving renal function or improving control of hypertension. However, recent controlled clinical trials cast doubt on the wisdom of this practice [24] . The Scottish and Newcastle Renal Artery Stenosis Collaborative Group randomized 55 patients [25] and the EMMA trial randomized 49 patients [26] with RAS to PTRA or aggressive medical therapy. After six months of follow-up, there were no significant overall advantages of intervention on BP in either trial. The DRASTIC study detected no differences in BP or GFR between patients with RAS followed up for one year after randomization to PTRA or medical therapy [6] .
One reason for the different conclusion from our study compared to controlled trials is that PTRAS has better A second reason that may account for differences between conclusion from this study and the controlled trials is the selection of patients. The DRASTIC study required only moderate or severe hypertension and a of patients with initially impaired renal function was Ͼ50% RAS. This will include many patients at an early maintained at a very high level of statistical significance.
stage of RAS that is not yet functionally significant, dilutThis study has some limitations. First, the GFR was ing the beneficial effects of PTRA in the overall results. calculated from the Cockcroft and Gault formula rather
In contrast, we used a combination of an anatomical than being measured directly by a clearance technique.
criterion of a stenosis of Ն70% and a functional criterion However, this method obviates errors due to incomplete of an arterial pressure gradient Ն30 mm Hg across the urine collection, and repeated measurements in the same stenosis, to eliminate patients with less severe RAS who individual (as in this study), minimize errors due to may not derive benefit from the procedure. These incluchanges in creatinine production [17] . Second, we screened sion criteria might help select the patients that will benefor re-stenosis by Doppler rather than by the invasive fit from PTRAS. On the other hand, as patients not method of arteriography. We selected Doppler because fulfilling the inclusion criteria were not submitted to it is very sensitive for detecting re-stenosis after PTRAS PTRAS, the possible benefit in these subjects cannot be [18] . Indeed, we found that the degree of RAS estimated excluded. Another study should be aimed to answer this by Doppler correlated closely with that measured diimportant point, that is, the relationship of the severity rectly by arteriography. The rates of re-stenosis after of vascular disease and the subsequent improvement ob-PTRAS are only 25% of those for PTRA alone [19] . tained after PTRAS. To answer this question, the variThird, the study lacked a control (untreated) group. Nevables to be assessed should be thresholds of anatomic ertheless, previous work has shown that atherosclerotic RAS tends to be progressive [7, 20] . In a recent study, RAS, trans-stenotic BP gradients, levels of baseline GFR, or other markers that could be useful to predict patient with normal renal function studied by split renal function methods, an improvement in GFR of the post-stenotic outcome and to be applied in decision-making.
Several other studies have evaluated renal function kidney after angioplasty is offset by a decline in GFR of the contralateral kidney that limits the beneficial efafter intervention for atherosclerotic RAS [7, 12, 27, 28] . Among the larger trials, Jensen et al studied 107 patients fects on overall GFR [35] . Discordant effects on GFR and BP in the group with an initially elevated S Cr may with atherosclerotic RAS over one year following PTRA [33] . There were significant (P Ͻ 0.001) reductions in be related to the persistence of residual renal dysfunction, since the GFR was not normalized after PTRAS. the BP and increases in the GFR. The GFR was measured from the plasma clearance of ( 51 Cr)-ethylenediamineIntrarenal vascular disease predicts a poor BP response to PTRA [12] . Despite the observed BP reduction was tetraacetic acid (EDTA) and increased from 48 Ϯ 24 mL · min Ϫ1 to 53 Ϯ 27 mL · min
Ϫ1
. This is very close to not significant for the subgroup with more severe impairment in renal function, considering the observed reducthe increase in calculated GFR from 54 to 62 mL · min Ϫ1 detected in the present series. Watson et al studied renal tion in the drug's number/dose, a response of lesser magnitude but of clinical value cannot be excluded, although function from the slope of the reciprocal of S Cr over time in 33 azotemic patients with atherosclerotic RAS before, to confirm this effect a higher number of patients would be required. In the trials comparing the effects on BP and for 20 months after PTRAS [34] . Renal function, which was deteriorating before the intervention, was staafter PTRAS, more patients were cured of hypertension in the group with an initially normal S Cr value [28] , as in bilized thereafter. Similar results were reported in a group of 23 patients with RAS whose deteriorating renal our study. Although renal dysfunction has been considered a marker of adverse outcomes after PTRAS [32], function was stabilized by PTRAS [23] . Our results extend these findings by demonstrating that beneficial efour results showing a significant improvement in GFR in patients with RAS and renal function impairment in fects on renal function may be anticipated in selected patients treated with PTRAS if their baseline renal funca sample of subjects younger than other reported series, raise questions about the prognostic role of other marktion is abnormal. Whether this result may imply an overall improvement in prognosis, based on the well-known ers like hypertension control (worse in those with previously altered GFR), age, and comorbidity. Studies deprognostic value of serum creatinine, or conversely, as serum creatinine was not entirely normalized, the relasigned with hard end points, prolonged follow-up and controlled interventions over the main treatable risk factive prognostic value of the baseline creatinine may be more important than serum creatinine at outcome after tors (such as hypertension, dyslipidemia, diabetes) are needed to find these answers PTRAS, remains a matter of speculation, but this issue deserves further study. Dorros et al did not address that Conclusions point, and they underscored the importance of PTRAS as a revascularization procedure before the onset of renal Two conclusions can be drawn from our study that, if confirmed, may help select patients most likely to benefit dysfunction in order to improve BP control, preserve or prevent renal function deterioration and patient survival from intervention. First, PTRAS can reduce BP and increase GFR over a mean of one year in a group of [32] . Based in our observations, the improvement of GFR after PTRAS in patients with decreased renal funcpatients carefully selected to have high grade anatomical RAS that is hemodynamically significant. Second, among tion resulting in a partial restoration or an interruption of the downward slope of renal function along the sponsuch selected patients, those with initially normal to mildly impaired renal function may anticipate an imtaneous evolution of ischemic nephropathy-as reported by Harden et al [23] and Watson et al [34]-supports a proved BP after intervention, whereas those with initially moderate to severely impaired renal function may anticivaluable therapeutic role for PTRAS in such patients, possibly delaying the onset of ESRD.
pate an improved GFR. This latter conclusion remains strongly supported after the correction for the RTM An interesting finding was the discordance between the beneficial effects of PTRAS on BP and GFR in the phenomenon in baseline GFR data. analysis of subgroups. The group with an initially higher GFR experienced a beneficial effect on BP without a ACKNOWLEDGMENTS change in GFR, whereas the group with an initially lower 
